Hereditary Spastic Paraplegia
New hereditary spastic paraplegia research, summarized each month in plain language.
2026 so far: So far in 2026 (January 2026 to September 2026), small human studies reported test-specific mobility gains from procedures, training, VR rehab, and walking aids; SPTSSA-HSP had an early, single-child treatment signal. Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- Spasticity procedures. In the months covered, a few small reports described procedures for spasticity, compared only to each person's baseline.
- Rehab and aids. In the months covered, training programs and walking supports often changed a few specific walking or balance measures.
- SPTSSA treatment signal. A gene-specific metabolic pathway was linked to a report in one treated child.
- Measuring change. In the months covered, new tests were explored, and some biomarkers looked limited over short follow-up.
- Getting a diagnosis. From January 2026 to September 2026, broader testing helped sort subtypes, but gaps in diagnosis remained.
New
September 2026
- SPTSSA treatment signal. One child with SPTSSA-HSP had less spasticity; evidence is early.
- Pediatric-to-adult care. Experts outlined transition steps, but outcomes were not tested.
- SPG4 blood-cell test. A blood-cell imaging measure separated SPG4 from controls in one study.
- Gait measure differences. Gait stability results varied widely with different calculation methods.
August 2026
- Walking aids. Sticks or a wheeled walker increased step length in short tests.
- VR balance training. A Wii-based program improved one part of a fall-risk test.
- SPG4 severity differences. Other genetic changes may contribute to more severe SPG4.
July 2026
- Childhood gene range. Similar childhood HSP symptoms came from many different genes.
- KIF1A symptom course. In KIF1A, stiffness often increased and independent walking decreased.
- Uncommon gene causes. Case reports added rare gene causes with additional symptoms.
- Gene-specific cell changes. Lab studies suggested gene-specific cell problems, not yet proven in people.
June 2026
- Robot walking practice. Robot-assisted walking was linked to better walking and balance tests.
- Foot-tapping test. Sensor foot-tapping separated HSP from controls, even in mild disease.
- Genetic testing yield. Targeted gene panels found more genetic diagnoses than older methods.
May 2026
- Genetic testing yield. Large genetic testing cohorts explained many people evaluated for hereditary spastic paraplegia, but some still had no clear genetic answer.
- Neurofilament in SPG4. Blood neurofilament levels were higher in SPG4, with the largest increases reported in people with more severe early disease.
- Lab pathway findings. Laboratory studies in AP-4–related HSP and SPG7 mapped cell pathways that could be adjusted in experiments.
April 2026
- Spasticity procedures. In early, small reports, spasticity decreased after procedures that change nerve or spinal cord signaling.
- Implanted spinal stimulation. After epidural spinal cord stimulation implants, some reports described better walking tests and quality-of-life scores than before implantation.
- SPG4 genetic testing. Genetic testing identified a range of SPAST (SPG4) changes, including deletions that remove parts of the gene.
- SPG11 lab findings. In laboratory models, SPG11 loss was linked to lysosome-related cell recycling problems and slower early nerve cell growth.
March 2026
- Muscle mass over time. In one small follow-up study, muscle mass decreased over time even though routine blood test results stayed similar.
- Thinking speed and attention. In a small study, people with HSP scored lower than controls on tests of thinking speed and attention.
- SPG4: broader symptoms reported. Reports in SPG4 (SPAST) described dementia in some people and certain brain findings in a subset.
- Nerve transport in the lab. Laboratory studies linked some HSP genes to disrupted transport inside nerve cells.
February 2026
- Lab targets in SPG4 and SPG76. In SPG4 and SPG76 lab models, changing specific cell pathways reduced HSP-like damage or movement problems, but these early results do not show symptom benefit in people.
- Blood marker over 9 months. In children with HSP, a blood marker of nerve cell injury stayed fairly stable over about 9 months and did not clearly line up with genetic subtype or baseline mobility.
- Hidden genetic variants. In SPG4 and SPG7, some non-coding DNA changes disrupted RNA splicing, and one SPG7 case showed how genome sequencing plus RNA testing can identify a second variant missed by standard panels.
January 2026
- Arm-crank exercise. Arm-crank workouts were workable for people with limited leg mobility.
- Medicines for symptoms. Single-patient reports linked some medicines to easier walking.
- Rate of change. Average worsening was slow, and faster in complicated HSP.
Get the monthly update by email
Subscribe here to receive an email when a new monthly hereditary spastic paraplegia update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).